ATYR PHARMA INC (ATYR)
US0021202025 - Common Stock
Taking everything into account, ATYR scores 2 out of 10 in our fundamental rating. ATYR was compared to 572 industry peers in the Biotechnology industry. ATYR has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ATYR is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
ATYR had negative earnings in the past year.
In the past year ATYR has reported a negative cash flow from operations.
In the past 5 years ATYR always reported negative net income.
ATYR had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -69.66%, ATYR is not doing good in the industry: 65.66% of the companies in the same industry are doing better.
With a Return On Equity value of -97.69%, ATYR perfoms like the industry average, outperforming 46.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.66% | ||
| ROE | -97.69% | ||
| ROIC | N/A |
ROA(3y)-39.44%
ROA(5y)-45.09%
ROE(3y)-49.97%
ROE(5y)-62.52%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ATYR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ATYR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ATYR has more shares outstanding
The number of shares outstanding for ATYR has been increased compared to 5 years ago.
Compared to 1 year ago, ATYR has a worse debt to assets ratio.
2.2 Solvency
ATYR has an Altman-Z score of -3.23. This is a bad value and indicates that ATYR is not financially healthy and even has some risk of bankruptcy.
ATYR has a Altman-Z score (-3.23) which is in line with its industry peers.
A Debt/Equity ratio of 0.02 indicates that ATYR is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.02, ATYR perfoms like the industry average, outperforming 42.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.23 |
ROIC/WACCN/A
WACC10.89%
2.3 Liquidity
A Current Ratio of 5.41 indicates that ATYR has no problem at all paying its short term obligations.
The Current ratio of ATYR (5.41) is comparable to the rest of the industry.
A Quick Ratio of 5.41 indicates that ATYR has no problem at all paying its short term obligations.
ATYR has a Quick ratio (5.41) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.41 | ||
| Quick Ratio | 5.41 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 3.09% over the past year.
ATYR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -97.81%.
ATYR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -67.68% yearly.
EPS 1Y (TTM)3.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15%
Revenue 1Y (TTM)-97.81%
Revenue growth 3Y-67.68%
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
The Earnings Per Share is expected to grow by 32.23% on average over the next years. This is a very strong growth
ATYR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 279.99% yearly.
EPS Next Y2.91%
EPS Next 2Y7.05%
EPS Next 3Y10.1%
EPS Next 5Y32.23%
Revenue Next Year-41.31%
Revenue Next 2Y163.26%
Revenue Next 3Y349.68%
Revenue Next 5Y279.99%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ATYR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ATYR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.05%
EPS Next 3Y10.1%
5. Dividend
5.1 Amount
ATYR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ATYR PHARMA INC
NASDAQ:ATYR (1/14/2025, 8:24:37 PM)
After market: 3.4168 +0.13 (+3.85%)3.29
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners63.64%
Inst Owner ChangeN/A
Ins Owners2.39%
Ins Owner Change0%
Market Cap276.16M
Analysts82.86
Price Target20.4 (520.06%)
Short Float %4.44%
Short Ratio4.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.38%
Min EPS beat(2)-2.5%
Max EPS beat(2)5.26%
EPS beat(4)2
Avg EPS beat(4)1.06%
Min EPS beat(4)-2.98%
Max EPS beat(4)5.26%
EPS beat(8)6
Avg EPS beat(8)14.45%
EPS beat(12)7
Avg EPS beat(12)5.64%
EPS beat(16)9
Avg EPS beat(16)3.85%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)187.99%
Min Revenue beat(4)-100%
Max Revenue beat(4)1051.96%
Revenue beat(8)2
Avg Revenue beat(8)640.84%
Revenue beat(12)2
Avg Revenue beat(12)393.89%
Revenue beat(16)3
Avg Revenue beat(16)370.26%
PT rev (1m)0%
PT rev (3m)-10.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.04%
EPS NY rev (1m)0.52%
EPS NY rev (3m)0.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)257.25%
Revenue NY rev (1m)-4.69%
Revenue NY rev (3m)-16.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1175.16 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.23 | ||
| P/tB | 4.23 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0
BVpS0.78
TBVpS0.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.66% | ||
| ROE | -97.69% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-39.44%
ROA(5y)-45.09%
ROE(3y)-49.97%
ROE(5y)-62.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 8.05% | ||
| Cap/Sales | 24.26% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.41 | ||
| Quick Ratio | 5.41 | ||
| Altman-Z | -3.23 |
F-Score1
WACC10.89%
ROIC/WACCN/A
Cap/Depr(3y)486.58%
Cap/Depr(5y)301.54%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15%
EPS Next Y2.91%
EPS Next 2Y7.05%
EPS Next 3Y10.1%
EPS Next 5Y32.23%
Revenue 1Y (TTM)-97.81%
Revenue growth 3Y-67.68%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-41.31%
Revenue Next 2Y163.26%
Revenue Next 3Y349.68%
Revenue Next 5Y279.99%
EBIT growth 1Y-45.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.6%
EBIT Next 3Y-11.5%
EBIT Next 5Y26.66%
FCF growth 1Y-67.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-69.3%
OCF growth 3YN/A
OCF growth 5YN/A